StreetInsider.com News Articles

Form SCHEDULE 13D Aligos Therapeutics, Filed by: BLATT LAWRENCE

Wed, 24 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260624/26685964.html

Form SCHEDULE 13D Aligos Therapeutics, Filed by: BLATT LAWRENCE

Wed, 24 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260624/26685964.html

Aligos Therapeutics (ALGS) Reiterated at Overweight by Cantor Fitzgerald

Fri, 29 May 2026 07:30:32 -0400

Cantor Fitzgerald analyst Steve Seedhouse reiterated an Overweight rating and $20.00 price target on Aligos Therapeutics Inc. (NASDAQ: ALGS).

The analyst commented, "Phase 3 chronic HBV treatment data for GSK's (not covered) bepirovirsen ("bepi") were presented at EASL and published in NEJM today. ~20% functional cure rate in low HBsAg-selected patients provides a "major step" forward (per NEJM editorial) for HBV standard-of-care. Novel therapeutics that drive deeper S antigen suppression should combine synergistically with bepi. ALGS's Pevifoscorvir ("pevi") may be one such molecule. Plus, Aligos may have a better version of bepi in its pre-clinical ASO ALG-170675. Below, we recap bepi

Lake Street Starts Aligos Therapeutics Inc. (ALGS) at Buy

Thu, 28 May 2026 08:54:28 -0400

(Updated - May 28, 2026 8:54 AM EDT)

Lake Street analyst Daniel Brims initiates coverage on Aligos Therapeutics Inc. (NASDAQ: ALGS) with a Buy rating and a price target of $45.00.

The analyst comments "We are initiating coverage of Aligos Therapeutics with a Buy rating and $45 PT, driven by sales of pevi in HBV (~$913M risk-adjusted 2040 sales). Pevi offers deeper suppression vs nucs and has the potential to be backbone therapy for in the evolving HBV landscape. Additional upside stems from a preclinical HBV pipeline (RNAi, PD-L1) targeting functional cure, which will be developed on top of pevi and ALG-055009,

Lake Street Starts Aligos Therapeutics Inc. (ALGS) at Buy

Thu, 28 May 2026 08:54:28 -0400

(Updated - May 28, 2026 8:54 AM EDT)

Lake Street analyst Daniel Brims initiates coverage on Aligos Therapeutics Inc. (NASDAQ: ALGS) with a Buy rating and a price target of $45.00.

Aligos presents hepatitis B drug data at liver conference

Wed, 27 May 2026 04:05:49 -0400

Aligos Therapeutics Inc. (NASDAQ: ALGS) presented data from ten studies at the European Association for the Study of the Liver Congress in Barcelona, Spain. The presentations focused on the company's hepatitis B treatment pevifoscorvir sodium and other experimental therapies.

In a follow-up study of patients who completed 96 weeks of pevifoscorvir sodium treatment followed by at least 24 weeks of standard nucleoside analog therapy, four of nine participants maintained undetectable hepatitis B virus DNA levels throughout the follow-up period. The study included patients with HBeAg-positive chronic hepatitis B infection who were treatment-naive or not currently receiving treatment.

Among participants with baseline HBsAg

Aligos presents hepatitis B drug data at liver conference

Wed, 27 May 2026 04:05:49 -0400

Among participants with baseline HBsAg

Aligos Therapeutics Presents Positive Data at the EASL Congress 2026

Wed, 27 May 2026 02:30:00 -0400

Long-term follow up data from the Phase 1 study of pevifoscorvir sodium continues to suggest a reduction in the cccDNA reservoir
Data on the preclinical characteristics of the Aligos/Amoytop ASO program to be presented
40% of HBeAg+ participants with chronic HBV infection treated with pevifoscorvir sodium at week 48 had reductions in HBsAg that would potentially allow them to qualify for ASO treatment

SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and

Aligos Therapeutics Presents Positive Data at the EASL Congress 2026

Wed, 27 May 2026 02:30:00 -0400

Long-term follow up data from the Phase 1 study of pevifoscorvir sodium continues to suggest a reduction in the cccDNA reservoir
Data on the preclinical characteristics of the Aligos/Amoytop ASO program to be presented
40% of HBeAg+ participants with chronic HBV infection treated with pevifoscorvir sodium at week 48 had reductions in HBsAg that would potentially allow them to qualify for ASO treatment

Aligos Therapeutics Presents Positive Data at the EASL Congress 2026

Wed, 27 May 2026 02:30:00 -0400

Long-term follow up data from the Phase 1 study of pevifoscorvir sodium continues to suggest a reduction in the cccDNA reservoir
Data on the preclinical characteristics of the Aligos/Amoytop ASO program to be presented
40% of HBeAg+ participants with chronic HBV infection treated with pevifoscorvir sodium at week 48 had reductions in HBsAg that would potentially allow them to qualify for ASO treatment

Aligos Therapeutics Presents Positive Data at the EASL Congress 2026

Wed, 27 May 2026 02:30:00 -0400

Long-term follow up data from the Phase 1 study of pevifoscorvir sodium continues to suggest a reduction in the cccDNA reservoir
Data on the preclinical characteristics of the Aligos/Amoytop ASO program to be presented
40% of HBeAg+ participants with chronic HBV infection treated with pevifoscorvir sodium at week 48 had reductions in HBsAg that would potentially allow them to qualify for ASO treatment

Cantor Fitzgerald Starts Aligos Therapeutics Inc. (ALGS) at Overweight

Thu, 21 May 2026 06:09:37 -0400

Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Aligos Therapeutics Inc. (NASDAQ: ALGS) with a Overweight rating and a price target of $20.00.

For an analyst ratings summary and ratings history on Aligos Therapeutics Inc. click here. For more ratings news on Aligos Therapeutics Inc. click here.

Shares of Aligos Therapeutics Inc. closed at $5.60 yesterday.

Form SCHEDULE 13G Aligos Therapeutics, Filed by: BLATT LAWRENCE

Fri, 15 May 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260515/26506573.html

Form SCHEDULE 13G Aligos Therapeutics, Filed by: BLATT LAWRENCE

Fri, 15 May 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260515/26506573.html

Form SCHEDULE 13G/A Aligos Therapeutics, Filed by: Woodline Partners LP

Fri, 15 May 2026 09:06:00 -0400

si-local-file:///var/storage/secattach/20260515/26500544.html

Form SCHEDULE 13G/A Aligos Therapeutics, Filed by: Woodline Partners LP

Fri, 15 May 2026 09:06:00 -0400

si-local-file:///var/storage/secattach/20260515/26500544.html

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

Wed, 13 May 2026 02:05:00 -0400

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ten abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2026, being held May 27 – 30, 2026 in Barcelona, Spain. The abstracts released today can be found on the EASL website at https://www.easlcongress.eu/.

Details on the abstracts are as follows:

Pevifoscorvir sodium: Potential first-/best-in-class small molecule CAM-E

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

Wed, 13 May 2026 02:05:00 -0400

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ten abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2026, being held May 27 – 30, 2026 in Barcelona, Spain. The abstracts released today can be found on the EASL website at https://www.easlcongress.eu/.

Details on the abstracts are as follows:

Pevifoscorvir sodium: Potential first-/best-in-class small molecule CAM-E

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

Wed, 13 May 2026 02:05:00 -0400

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ten abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2026, being held May 27 – 30, 2026 in Barcelona, Spain. The abstracts released today can be found on the EASL website at https://www.easlcongress.eu/.

Details on the abstracts are as follows:

Pevifoscorvir sodium: Potential first-/best-in-class small molecule CAM-E

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

Wed, 13 May 2026 02:05:00 -0400

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ten abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2026, being held May 27 – 30, 2026 in Barcelona, Spain. The abstracts released today can be found on the EASL website at https://www.easlcongress.eu/.

Details on the abstracts are as follows:

Pevifoscorvir sodium: Potential first-/best-in-class small molecule CAM-E

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

Wed, 13 May 2026 02:05:00 -0400

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ten abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2026, being held May 27 – 30, 2026 in Barcelona, Spain. The abstracts released today can be found on the EASL website at https://www.easlcongress.eu/.

Details on the abstracts are as follows:

Pevifoscorvir sodium: Potential first-/best-in-class small molecule CAM-E

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

Wed, 13 May 2026 02:05:00 -0400

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ten abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2026, being held May 27 – 30, 2026 in Barcelona, Spain. The abstracts released today can be found on the EASL website at https://www.easlcongress.eu/.

Details on the abstracts are as follows:

Pevifoscorvir sodium: Potential first-/best-in-class small molecule CAM-E

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

Wed, 13 May 2026 02:05:00 -0400

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ten abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2026, being held May 27 – 30, 2026 in Barcelona, Spain. The abstracts released today can be found on the EASL website at https://www.easlcongress.eu/.

Details on the abstracts are as follows:

Pevifoscorvir sodium: Potential first-/best-in-class small molecule CAM-E

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

Wed, 13 May 2026 02:05:00 -0400

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ten abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2026, being held May 27 – 30, 2026 in Barcelona, Spain. The abstracts released today can be found on the EASL website at https://www.easlcongress.eu/.

Details on the abstracts are as follows:

Pevifoscorvir sodium: Potential first-/best-in-class small molecule CAM-E

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

Wed, 13 May 2026 02:05:00 -0400

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ten abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2026, being held May 27 – 30, 2026 in Barcelona, Spain. The abstracts released today can be found on the EASL website at https://www.easlcongress.eu/.

Details on the abstracts are as follows:

Pevifoscorvir sodium: Potential first-/best-in-class small molecule CAM-E